https://orcid.org/0000-0003-0213-5470
References
- Giles ML, Wallace EM, Alpren C, Brady N, Crouch S, Romanes F, Sutton B, Cheng A. Suppression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after a second wave in Victoria, Australia. Clin Infect Dis. 2021;73(3):e808–6. doi:10.1093/cid/ciaa1882 .
- World Health Organization (WHO). Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance, 3 February 2021. 2021 [accessed 2021 Nov 18]. https://apps.who.int/iris/handle/10665/339452 .
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–101. doi:10.1056/NEJMoa2104840 .
- Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331–40. doi:10.1001/jama.2021.24110 .
- World Health Organization (WHO). Global vaccine safety blueprint 1.0. 2012 [accessed 2022 Feb 17]. https://apps.who.int/iris/handle/10665/70919 .
- Horvath J. Review of the management of adverse effects associated with Panvax and Fluvax. 2011 [accessed 2022 Feb 20]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/53AE51CDFBC05086CA257D7A001A758A/$File/adverse-event-march-2011.pdf .
- Austalian Bureau of Statistics. National, state and territory population. 2020 [accessed 2021 Dec 17]. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release#states-and-territories .
- Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294–98 .
- World Health Organization (WHO). Global vaccine safety blueprint 2.0. 2021 [accessed 2022 Feb 20]. https://www.who.int/publications/i/item/10665348966_9789240036963 .
- Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report - 08-07-2021. 2021 [accessed 2021 Dec 17]. https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-08-07-2021 .
- Therapeutic Goods Administration (TGA). Reporting suspected side effects associated with a COVID-19 vaccine. 2021 [accessed 2021 Dec 18]. https://www.tga.gov.au/reporting-suspected-side-effects-associated-covid-19-vaccine .
- Clothier HJ, Lawrie J, Lewis G, Russell M, Crawford NW, Buttery JP. SAEFVIC: surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Commun Dis Intell. 2018;2020:44.
- Austalian Bureau of Statistics. 2016 census QuickStats: greater Melbourne. 2016 [accessed 2021 Dec 17]. https://www.abs.gov.au .
- Gordon SF, Clothier HP, Morgan H, Buttery JP, Phuong LK, Monagle P, Chunilal S, Wood EM, Tran H, Szer J, et al. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine. 2021;39:7052–57. doi:10.1016/j.vaccine.2021.10.030 .
- Osowicki J, Morgan H, Harris A, Crawford NW, Buttery JP, Kiers L. Guillain-Barré Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines. Ann Neurol. 2021;90(5):856–58. doi:10.1002/ana.26218 .
- Melbourne Vaccine Education Centre (MVEC). COVID-19 vaccine safety information. 2021 [accessed 2021 Nov 18]. https://mvec.mcri.edu.au/covid-19/ .
- Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNtech COVID-19 vaccine. JAMA. 2021;325(8):780–81. doi:10.1001/jama.2021.0600.
- Victorian Department of Health. Victoria COVID-19 data. 2021 [accessed 2021 Dec 11]. https://www.coronavirus.vic.gov.au/victorian-coronavirus-covid-19-data .
- Melbourne Vaccine Education Centre. Victorian Specialist Immunisation Services (VicSIS). 2021 [accessed 2021 Nov 11]. https://mvec.mcri.edu.au/references/the-vicsis-victorian-specialist-immunisation-services-network/ .
- Australian Technical Advisory Group on Immunisation (ATAGI). ATAGI statement regarding vaccination of adolescents aged 12-15 years. 2021 [accessed 2021 Nov 18]. https://www.health.gov.au/news/atagi-statement-regarding-vaccination-of-adolescents-aged-12-15-years .
- Australian Technical Advisory Group on Immunisation (ATAGI). ATAGI recommendations on Pfizer COVID-19 vaccine use in children aged 5 to 11 years. 2021 [accessed 2021 Dec 12]. https://www.health.gov.au/resources/publications/atagi-recommendations-on-pfizer-covid-19-vaccine-use-in-children-aged-5-to-11-years .
- Australian Department of Health. National immunisation program schedule. 2021 [accessed 2021 Dec 12]. https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule .